While US death rates from prostate cancer (PC) have fallen about 4% per year since 1992, five years after the introduction of prostate-specific-antigen (PSA) testing, at the same time recent reports and practice guidelines cite the unproven benefit of PSA screening showing that it comes at the cost of substantial risk of overdiagnosis and overtreatment - with known downstream adverse effects. To date, the issue of PSA testing remains controversial economically and socially. The key question is not whether PSA screening is effective, but whether it does more good than arm. As a consequence, there is a striking need for new predictive biomarkers in prostate carcinogenesis.
Our consortium brings together specialists in functional genomics and RNAi, in nanotechnology, in prostate cancer biology and proposes to take advantages of the recent progress in nanoparticles (Lipidots®; a patented technology of lipid nanoparticles) design and synthesis to develop a new technological platform for large scale functional genomics applied to biomarker discovery in PC.
Projet FacsBiomarker (Prostate Cancer)
- Projet FacsBiomarker (Prostate Cancer)
- Projet Cancer & Ubiquitin (Prostate Cancer)
- Projet RNAi-based High Content Screening
 Project leader |
||
|
||
|
|